Protagenic Therapeutics (NASDAQ:PTIX) Stock Price Up 1.4% – Should You Buy?

Shares of Protagenic Therapeutics, Inc. (NASDAQ:PTIXGet Free Report) shot up 1.4% during mid-day trading on Wednesday . The company traded as high as $0.58 and last traded at $0.56. 64,745 shares changed hands during trading, a decline of 24% from the average session volume of 84,875 shares. The stock had previously closed at $0.55.

Protagenic Therapeutics Stock Up 1.5 %

The stock’s 50-day moving average price is $0.64 and its 200-day moving average price is $0.96. The company has a market capitalization of $2.44 million, a price-to-earnings ratio of -0.39 and a beta of 0.27.

Protagenic Therapeutics (NASDAQ:PTIXGet Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter.

Protagenic Therapeutics Company Profile

(Get Free Report)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.

Featured Stories

Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.